Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), started a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in June, 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in 2021.
Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, entered a phase 2a proof of concept clinical study for the treatment of epilepsy in June 2021.
Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction.
Other preclinical programs include:
Addex was founded in 2002, headquartered in Geneva, Switzerland and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN since 2007, and on the NASDAQ exchange also under the trading symbol ADXN since 2020.
Find out more about our Clinical and Pre-Clinical Pipeline.